Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 24,966 shares at $44.17 ($1.1M) on 2025-09-08, disclosed to the SEC on 2025-09-10.
Scheduled sale ($1.1M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.17 | 12,466 | $551K | 49.9% |
| 2 | $44.17 | 12,466 | $551K | 49.9% |
| 3 | $44.88 | 34 | $2K | 0.1% |
| Total | $44.17 avg | 24,966 | $1.1M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $124K | — | Filing → |